Figure 3.

Systemic administration of CM-miR-143 lipoplexes suppressed tumor growth of CRC pelvic recurrence mouse

(A) Scheme of in vivo experiments to measure fluorescence. Mice were randomly divided into 2 groups after tumor formation. To measure fluorescence, miRNA lipoplexes (330 μg/kg miRNA per administration) were injected into the tail vein 3 times over 10 days. (B) All IVIS images of control (C) and CM-miR-143 (CM-143) at days 0, 3, 7, and 10 posttreatment in the DLD-1 clone#1-Luc mouse model and the HT-29-Luc mouse model are shown. (C) Fluorescence intensity was measured on days 0, 3, 7, and 10 posttreatment using IVIS in DLD-1 clone#1-Luc and HT-29-Luc mouse models (DLD-1 clone#1-Luc: n = 11, HT-29-Luc: n = 11). The graph shows variation in fluorescence intensity over time. Fold changes in fluorescence intensity were analyzed per group. In the DLD-1 clone#1-Luc mouse model, the CM-miR-143 group experienced significantly suppressed fluorescence intensity on days 3, 7, and 10 posttreatment compared with the control group; in the HT-29-Luc mouse model, significant suppression occurred only on day 10. Black arrowheads indicate the injection of miRNA lipoplexes into the tail vein. Data are presented as mean ± SEM (∗p < 0.05).